Mining / Road Transport
Optalert’s early warning drowsiness detection technology, protecting industry for over 20 years. Improved safety, with maximum productivity.
Licensing
Optalert’s automotive algorithm. Tier 1 Automotive companies now have the opportunity to partner with Optalert to licence the drowsiness algorithm for integration into Driver Monitoring Systems.
Pharmaceutical
BlinQ system, the next generation in measuring drowsiness/wakefulness in clinical drug trials. Determine efficacy, safety and the right dose.
Neurology Research
Optalert gives researchers the potential to identify, track and detect precursors or changes in neurological disorders for early intervention.
Renowned as experts in drowsiness/wakefulness detection, Optalert is now exploring new pathways in the automotive industry, pharmaceutical drug trials and neurological research. Sign up today to keep up to date with the latest news from Optalert.
Dr Murray John’s latest publication – Now available
The Assessment of ‘Sleepiness’ in Human Drug Trials: A New Perspective
Current Psychopharmacology 2019, Volume 8 , Issue 1
OPTALERT’S EARLY-WARNING SYSTEM IS TRUSTED BY MAJOR GLOBAL BLUE CHIP COMPANIES
